Navigation Links
Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma

esigned to evaluate the efficacy and safety of VCP in relapsed / refractory MM patients. The study included 13 evaluable patients, who received VELCADE at 1.5 mg/m2 on days 1, 8 and 15 of a 28-day schedule. Patients also received 300 mg/m2 of cyclophosphamide on days 1, 8, 15 and 22 and prednisone at 100 mg every two days. Patients were treated for up to eight cycles. Response was assessed by the European Group for Blood and Marrow Transplant (EBMT) criteria. Results were presented by Dr. Reece and showed an ORR (CR + partial response + minor response) of 93 percent, including a high CR rate of 54 percent. At one year, all patients were alive (one-year survival rate). Therapy demonstrated excellent patient tolerance with side effects similar to those seen with each agent alone.

Phase II Study of VELCADE, Lenalidomide and Dexamethasone in Relapsed / Refractory Multiple Myeloma (Abstract #PO-660)

The Phase II multi-center study evaluated the efficacy and safety of this novel combination therapy. The trial included 19 evaluable relapsed / refractory MM patients, including those who had received prior VELCADE, lenalidomide, thalidomide or stem cell transplantation. The patients received VELCADE at 1.0 mg/m2 on days 1, 4, 8 and 11 of a 21-day schedule; lenalidomide at 15 mg on days 1 through 14; and dexamethasone at 40 mg for cycles one through four and 20 mg for cycles five through eight. Patients received a median of five cycles. Responses were assessed using the EBMT criteria. Results were presented by Paul Richardson, M.D., Dana-Farber Cancer Institute, and showed a 68 percent ORR, including a CR rate of 5 percent. Therapy was well tolerated with no grade 3 or higher toxicities.

About Multiple Myeloma

Multiple myeloma is the second most common hematologic malignancy and although the disease is predominantly a cancer of the elderly (the average age of onset is 65 to 70 years of age), recent statistics indicate both increasing incidence and
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
3. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
4. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
10. Aquavan (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007
11. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
Post Your Comments:
(Date:11/21/2014)... , Nov. 21, 2014 ... the European Medicines Agency (EMA) has granted ... company,s lead product candidate, for the treatment ... a rare, severely disabling genetic disease characterized ... swelling (flare-ups) and new abnormal bone formation. ...
(Date:11/21/2014)... 20, 2014  RedRick Technologies, a provider of ... room environment guidance, has helped the new Penn ... room, which may also serve as a model ... "In line with the tenets ... Radiology,s Imaging 3.0 ™ initiative, the new ...
(Date:11/21/2014)... CORAL GABLES, Fla. , Nov. 20, 2014 /PRNewswire/ ... working to become the first U.S. commercial producer of ... signed a contract with INVAP to design ... Alachua, Fla. Mo-99 is the parent isotope ... nuclear medicine procedures worldwide. In 2012, Congress passed legislation ...
Breaking Medicine Technology:Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 2RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 3Coqui RadioPharmaceuticals Inks Deal With INVAP 2
... Trust, Inc. (NYSE: BMR ) announced ... with Omeros Corporation (NASDAQ: OMER ) ... Seattle, Washington.  A clinical-stage biopharmaceutical company committed to ... coagulopathies and disorders of the central nervous system, Omeros ...
... Feb. 1, 2012 Novartis announced today that following ... (FDA) has approved an update to the Gleevec ® ... of treatment after surgery for adult patients with KIT ... of recurrence inclusion criteria of the pivotal trial. This ...
Cached Medicine Technology:BioMed Realty and Omeros Sign New 64,500 Square Foot Lease in Seattle 2BioMed Realty and Omeros Sign New 64,500 Square Foot Lease in Seattle 3BioMed Realty and Omeros Sign New 64,500 Square Foot Lease in Seattle 4FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery 2FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery 3FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery 4FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery 5FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery 6FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery 7FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery 8
(Date:11/23/2014)... November 23, 2014 The report, ... 2006 to 2020 - Asia-Pacific” provides quantitative analysis ... market segments: minimally invasive body contouring devices, non-invasive ... analysis includes market size data by revenue and ... following countries: China, Japan, South Korea, Australia and ...
(Date:11/23/2014)... 2014 (HealthDay News) -- The holidays can be a ... overload can trigger major meltdowns, an expert says. ... of circumstances, but when you have children with special ... occupational therapy professor at University of the Sciences in ... best to let your hosts or visitors know what ...
(Date:11/23/2014)... 23, 2014 More than two dozen ... a federal litigation involving Byetta lawsuits ( http://www.byettalawsuit2013.com/ ), ... Liebhard LLP reports. , A Case List updated ... class of Type 2 diabetes medications referred to as ... District Court, Southern District of California, where a federal ...
(Date:11/23/2014)... November 23, 2014 Syngenta lawsuits are ... behalf of farmers and agribusinesses that have allegedly incurred ... commercialize Agrisure Viptera and Agrisure Duracade, genetically modified ... approved for sale in China. According to a report ... virtually ban U.S. corn imports. Because China is the ...
(Date:11/22/2014)... 2014 A new AlignLife Chiropractic & ... the downtown Greenville area. Dr. Chelsea Sineath, owner and ... to open her own clinic after working in another ... patients. , AlignLife believes that the body can ... focus on chiropractic care and rehabilitation to allow the ...
Breaking Medicine News(10 mins):Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 3Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 4Health News:Holidays Can Be Sensory Overload for Kids With Autism 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 3Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 4Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 2Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 3Health News:AlignLife of Downtown Greenville is Now Open and Accepting New Patients 2
... 28 (HealthDay News) -- While the hormone oxytocin makes people ... study shows. Oxytocin -- a naturally occurring hormone that ... an important role in social behavior. Increased levels of the ... overall caring, generosity and trust, but it hasn,t been known ...
... of the most spectacular migrations on Earth is that of ... Acknowledged as one of the wonders of the natural world, ... five-kilometre breeding migration. Now, scientists have discovered the key to ... a team led by the late Professor Steve Morris from ...
... Traumatic brain injury, currently considered a singular event ... is instead the beginning of an ongoing process that ... other diseases and disorders that can reduce life expectancy, ... Branch at Galveston. As such, traumatic brain injury ...
... study not only has confirmed that children who have ... more prone to emotional problems, but many of those ... or peer violence that could exacerbate those issues. ... on top of exposure to disaster had more anxiety, ...
... a small and cheap-to-build unmanned aerial vehicle (UAV) intended ... reduce risks to material and human lives. The seaplane ... plane to fly in severe weather conditions. The resulting ... payload of up to 40 kg. It is equipped ...
... single cochlear implant capable of giving sound in both ears ... of the South of England Cochlear Implant Centre (SOECIC), based ... is an electronic device that can help both adults and ... has two parts: an internal receiver/stimulator package and electrode array, ...
Cached Medicine News:Health News:Oxytocin Increases Trust, Not Gullibility 2Health News:Scientists discover key to Christmas Island's red crab migration 2Health News:Researchers urge reclassification of traumatic brain injury as chronic disease 2Health News:Researchers urge reclassification of traumatic brain injury as chronic disease 3Health News:Researchers urge reclassification of traumatic brain injury as chronic disease 4Health News:Victimized children involved with disasters more likely to have mental health issues 2Health News:Victimized children involved with disasters more likely to have mental health issues 3Health News:Shape-shifting robot plane offers safer alternative for maritime rescue 2Health News:Shape-shifting robot plane offers safer alternative for maritime rescue 3Health News:Southampton to conduct UK's first cochlear implant operation to give sound in both ears 2
The Synoptiscope(L-2510B) has a wide variety of functions including binocular function diagnosis and treatment....
Inquire...
Security and confidence assured with porous tape; integral deodorizing/venting filter....
Inquire...
Medicine Products: